Nrf2 | Kuria Therapeutics

Keith Ward

Apr 21

Kuria to present at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2025

- Kuria to present positive preclinical proof-of-concept data for lead NRF2 activator for both cornea and retina disease Kuria...

Keith Ward

Sep 8, 2023

- Expands development pipeline with planned Phase 2 clinical trial for dry AMD Kuria Therapeutics, a pharmaceutical company developing a...

Keith Ward

Jun 27, 2022

Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2...